Seeking Alpha
Profile| Send Message|
( followers)  

Following is the list of 22 companies with market cap > $50 million and consensus growth rates for 2011 and 2012 that are greater than 100%.

Ticker

Company Name

FY-Dec.10

FY-Dec.11

FY-Dec.12

Market Cap

Year To Date Stock Return

Last 1 Year Stock Return

FOLD

Amicus Therapeutics, Inc.

0.92

7.98

16.24

176.7

36%

65%

ASTI

Ascent Solar Technologies, Inc.

1.46

3.9

41.7

107.31

-1%

-23%

AVNR

Avanir Pharma

3.7

29.73

131.69

455.9

-8%

99%

CORT

Corcept Therapeutics Incorporated

0.12

4

31.49

312.53

-2%

43%

CYTK

Cytokinetics

2.58

9.58

36.02

100.14

-26%

-51%

DNDN

Dendreon

47.79

372.58

867.94

4770.07

-4%

4%

GBG

Great Basin

95.28

341.7

381.11

1076.44

-12%

60%

HOKU

Hoku Corp.

6.15*

64.2**

216.8***

110.09

-24%

-10%

KOG

Kodiak Oil

32.71

158.8

317.88

1254.3

9%

192%

NSPH

Nanosphere

2.03

4.88

17.74

92.6

-25%

-26%

OTCPK:NGSX

NeurogesX

8.29

17.14

48.08

69.51

-39%

-50%

NOG

Northern Oil

61.48

177.59

313.45

1919.34

16%

159%

OREX

Orexigen

0.88

13.18

27.45

157.02

-59%

48%

PACB

Pacific Biosciences

1.67

33.52

138.78

831.96

-1%

4%

PLX

Protalix

9.6

51.75

75.13

619.65

-23%

9%

QPSA.OB

Quepasa Corp.

6.05

15.03

35.59

155.51

-13%

189%

SVNT

Savient Pharma

4.03

42.39

120.19

692.04

-12%

-27%

SSRI

Silver Standard

120.91

248.77

307.71

2056.91

6%

56%

STWD

Starwood Properties

84.61

201.38

261.73

1668.91

8%

25%

TAT

TransAtlantic

80.36

187.37

319.62

1059.8

-5%

-1%

TSPT

Transcept Pharma

12.5

37.35

33.85

118.74

19%

20%

VRTX

Vertex Pharma

143.37

641.69

2,211.86

8908.32

28%

10%

*FY-Mar.11, **FY-Mar.12, ***FY-Mar.13

Note: Since many of these companies are biotech companies dependent on the success of one molecule, actual earnings may vary substantially from the estimates. Also, some of these companies are smaller ones covered by just one or two analysts and any error, lack of understanding or timely update on the part of analysts are likely to be reflected in the estimates. Nevertheless, the list is a good starting point for traders to identify where the action might be going forward.

Business Brief (Source: Reuters)

Amicus Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones. The company's lead product candidate, Amigal (migalastat hydrochloride) for Fabry disease, is in Phase III development. Its other clinical stage product candidates are AT2220 (1-deoxynojirimycin HCl) for Pompe disease, which, as of December 31, 2009, was in Phase I testing and remains on partial clinical hold, and Plicera (afegostat tartrate) for Gaucher disease. The company is conducting preclinical studies in diseases of neurodegeneration, including Parkinson's and Alzheimer's.

Ascent Solar Technologies, Inc. is a development stage company formed to commercialize flexible photovoltaic (PV) modules using a technology. The company's manufacturing process deposits multiple layers of materials, including a thin film of copper-indium-gallium-diselenide (CIGS) semiconductor material, on a flexible, lightweight, plastic substrate and then laser patterns the layers to create interconnected PV cells, or PV modules, in a process known as monolithic integration. The company's thin-film PV modules require less than 1% of the semiconductor material to achieve the same power output as a c-Si-based PV device.

Avanir Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare (NYSE:GSK), is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved Nuedexta, a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders. The company focuses on the disorders that are associated with a steroid hormone called cortisol. The company is developing its lead product, Corlux, a potent glucocorticoid receptor II (GR-II) antagonist that blocks the activity of cortisol. It is developing Corlux for the treatment of the psychotic features of psychotic major depression under an patent license from Stanford University.

Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The company's research and development programs relating to the biology of muscle function are directed to small molecule modulators of the contractility of cardiac, skeletal and smooth muscle. The cardiac muscle contractility program is focused on cardiac muscle myosin, a motor protein that powers cardiac muscle contraction. The drug candidate from this program, CK-1827452, is a cardiac muscle myosin activator. In January 2009, the company announced the selection of a potential drug candidate that modulates smooth muscle contractility. This compound is a direct inhibitor of smooth muscle myosin, the motor protein central to the contraction of smooth muscle that causes the relaxation of contracted smooth muscle.

Dendreon Corp. is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. The company's product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. Its advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed three Phase III trials for the treatment of metastatic, castrate-resistant, (also known as androgen-independent or hormone-refractory) prostate cancer. Its lead product candidate, Provenge (sipuleucel-T), is designed to target the prostate cancer antigen prostatic acid phosphatase (PAP), an antigen that is expressed in more than 90 % of all prostate cancers. The antigen target for Neuvengetm (lapuleucel-T), its active immunotherapy candidate in development for the treatment of bladder, breast, ovarian and other solid tumors, is a HER2/neu.

Great Basin Gold Ltd. is engaged in the acquisition, exploration, development and trial mining of precious metal deposits. The company has two material projects, both of which are at the trial mining stage, which consists of the Hollister gold project and the Burnstone gold project. The company is also conducting early stage exploration on a number of other prospects, primarily in Tanzania and Mozambique. The Esmeralda property was for its ore-processing facility, which the company renovated. During 2009, the company generated revenue of $33.7 million (U.S.$28 million) from its Hollister operation. The ore was sold under the terms of various toll milling and ore purchase agreements to Newmont Mining Corporation (NYSE:NEM) and Echo Bay Minerals Company (ECO).

Hoku Corp., formerly Hoku Scientific, Inc., is a diversified clean energy technologies company with three business units: Hoku Materials, Hoku Solar and Hoku Fuel Cells. The company has three operating segments in two industries: Fuel Cell and Solar. The Fuel Cell industry is comprised of the fuel cell segment. The Solar industry is comprised of the photovoltaic (PV) system installation and the polysilicon production segments. Hoku Corp. installed the first six out of a planned total order of 28 Siemens-process reactors at the Polysilicon Plant and in April 2010, produced polysilicon using two of the six reactors. The company is a provider in PV system installations. Under the name Hoku Fuel Cells, Hoku Corp. operates its fuel cell business, which has designed, developed and manufactured membranes and membrane electrode assemblies (MEAs), for proton exchange membrane (PEM) fuel cells.

Kodiak Oil & Gas Corp., incorporated on March 17, 1972, is an independent energy company focused on the exploration, exploitation, acquisition and production of natural gas and crude oil in the United States. The company's oil and natural gas reserves and operations are concentrated in two Rocky Mountain Basins, the Williston Basin of North Dakota and Montana, and the Green River Basin of Wyoming and Colorado. As of December 31, 2009, the company's portfolio included Eastern Bakken oil play in Mountrail and Dunn Counties, North Dakota, and Vermillion Basin of southwest Wyoming. As of December 31, 2009, the company had acquired an interest in approximately 52,000 gross (37,000 net) acres in the Eastern Bakken oil play. It has drilled its first two wells on the prospect acreage. As of December 31, 2009, the company controlled approximately 43,000 gross acres and 16,000 net acres in the Vermillion Basin.

Nanosphere, Inc. is engaged in developing, manufacturing and marketing a molecular diagnostics platform, the Verigene System, that enables genomic and protein testing on a single platform. The company's nanoparticle technology simplifies molecular diagnostic testing, provides the ability to run multiple tests simultaneously on the same sample and has the potential to run a menu of tests on a single platform. The company is developing diagnostic tests for markers, which reveal the existence of a range of medical conditions including cardiovascular, respiratory, cancer, autoimmune, neurodegenerative and other infectious diseases, as well as for pharmacogenomics.

NeurogesX Inc. is a biopharmaceutical company focused on developing and commercializing pain management therapies. The company is assembling a portfolio of pain management product candidates based on known chemical entities. Its initial focus is on the management of chronic peripheral neuropathic pain conditions. The company's commercial product Qutenza, is a dermal delivery system designed to treat certain neuropathic pain conditions and was approved by the United States FDA in November 2009 for the management of neuropathic pain associated with postherpetic neuralgia (PHN).

Northern Oil & Gas Inc. is an independent energy company engaged in the acquisition, exploration, exploitation and development of oil and natural gas properties. It is focused on the activities primarily on projects based in the Rocky Mountain Region of the United States, specifically the Bakken and Three Forks/Sanish formations within the Williston Basin. As of March 1, 2010, the group owned working interests in 188 successful discoveries, consisting of 185 targeting the Bakken/Three Forks formation and three targeting a Red River structure. As of December 31, 2009, the group completed drilling on approximately 10% of the Bakken prospective acreage inventory assuming 640-acre spacing units. As of December 31, 2009, its principal assets included approximately 104,000 net acres located in the Williston Basin region of the northern United States and approximately 10,000 net acres located in Yates County, New York.

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Its combination product candidates targeted for obesity are Contrave, which has completed Phase III clinical trials, and Empatic, which has also completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release (SR) formulation. Bupropion is a prescribed antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction. Empatic is a combination of bupropion SR and zonisamide SR. Zonisamide, in a release formulation, was approved in the United States for the adjunctive treatment of partial seizures, a form of epilepsy. These product candidates regulate appetite and energy expenditure through the central nervous system (CNS).

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on the ProCellEx protein expression system. Using the ProCellEx system, the company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on the plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. The ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. The ProCellEx protein expression system is built on bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures.

Quepasa Corp., through its website Quepasa.com, is an online social communitiy for young Hispanics. Quepasa.com provides users with access to an expansive, multilingual menu of resources that promote social interaction, information sharing, and other topics of importance to Hispanic users. Quepasa.com is available in Spanish, English and Portuguese. The company provides Website to enable Hispanics to share their interests, ideas and activities to help them embrace their heritage. Once signed up, members can create a profile page and personalize their page with a variety of background designs, photos, slideshows and videos that allow members to creatively express themselves. The company's membership base consists of Hispanics in the United States, Mexico, Brazil and other Latin American countries. In March 2009, it launched Quepasa in Brazil.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing Krystexxa (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. The company sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company operates within the Specialty Pharmaceutical segment, which includes sales of Oxandrin and oxandrolone, and the research and development activities of Krystexxa. In its replicate randomized, double-blind, placebo-controlled, Phase III clinical trials, Krystexxa, a biologic PEGylated uricase enzyme, demonstrated the normalization of uric acid, complete resolution of tophi, improvement in chronic pain, improvement of physical functioning and decreased frequency of gout flares in patients with chronic gout.

Silver Standard Resources Inc. is a silver resource company that assembled a portfolio of silver-dominant projects located in seven countries in the Americas and Australia. The company's project, Pirquitas, is focused on operating and producing silver. The company is focused on advancing its five other principal projects, including the San Luis project, the Pitarrilla project, the Diablillos project, the Snowfield project and the Brucejack project.

Starwood Property Trust, Inc. is focused primarily on originating, investing in, financing and managing commercial mortgage loans and other commercial real estate debt investments, commercial mortgage-backed securities (CMBs), and other commercial real estate-related debt investments. It also invests in residential mortgage loans and residential mortgage-backed securities (RMBs). The company invests in target assets secured primarily by United States collateral.

TransAtlantic Petroleum Ltd., formerly TransAtlantic Petroleum Corp., is an international oil and gas company engaged in the acquisition, development, exploration, and production of crude oil and natural gas. The company holds interests in developed and undeveloped oil and gas properties in Turkey, Morocco, Romania, and California. It owns its own drilling rigs and oilfield service equipment, which it uses to develop its properties in Turkey and Morocco. In addition, it provides oilfield services and contract drilling services to third parties in Turkey. As of March 15, 2010, TransAtlantic Petroleum Ltd. was producing an aggregate of approximately 2,500 gross barrels of oil per day from the Selmo and Arpatepe oil fields. On July 23, 2009, the company's wholly owned subsidiary, TransAtlantic Worldwide Ltd., acquired all of the ownership interests in Energy Operations Turkey, LLC. During the year ended December 31, 2009, it acquired Incremental Petroleum Limited.

Transcept Pharmaceuticals, Inc., formerly Novacea, Inc., is a specialty pharmaceutical company focused on the development and commercialization of products that address important therapeutic needs in neuroscience. The company's most advanced product candidate, Intermezzo (zolpidem tartrate sublingual tablet), is a sublingual low dose formulation of zolpidem that it is developing for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. On January 30, 2009, it completed a business combination, or merger with Transcept Pharmaceuticals, Inc. (TSPT). Intermezzo utilizes Bimucoral technology, a bicarbonate-carbonate binary buffer system, or a chemical combination that modifies the pH of saliva, to convert water-soluble zolpidem tartrate into its fat-soluble free-base form, which is absorbed through the tissues of the mouth. The Intermezzo sublingual dosage form is formulated to deliver zolpidem to allow patients to return to sleep.

Vertex Pharmaceuticals Inc. is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Telaprevir, the company's lead drug candidate, is an oral hepatitis C protease inhibitor and a new class of antiviral treatments in clinical development that target hepatitis C virus (HCV), infection. Telaprevir is being evaluated in a registration program focused on treatment-naive and treatment-failure patients with genotype 1 HCV infection. VX-770, the lead drug candidate in its cystic fibrosis (CF), program is being evaluated in a registration program that focuses on patients with CF who have the G551D mutation in the gene responsible for CF. Vertex is conducting a number of Phase IIa clinical trials of its earlier-stage drug candidates. On March 12, 2009, Vertex acquired ViroChem Pharma Inc.

Source: 22 Companies With Market Cap Over $50 Million and 100%-Plus Sales Growth Forecast for 2011-12